ViGeneron GmbH, a clinical-stage gene therapy firm, has initiated a Phase Ib clinical trial for VG901, a novel treatment for retinitis pigmentosa (RP) caused by CNGA1 gene mutations.

In a recent clinical study, two patients with advanced cancers, one with melanoma and the other with pancreatic cancer, experienced a complete disappearance of their targeted tumors.

Monopar Therapeutics, a biopharmaceutical firm listed on Nasdaq as MNPR, has initiated a Phase 1 clinical trial for a novel imaging agent, MNPR-101-Zr.

A recent study presented at the 2024 AACR highlighted the potential of SKB264, an antibody-drug conjugate (ADC) developed by Merck and Kelun-Biotech, in treating gastric and gastroesophageal junction cancers.

Boundless Bio, a clinical-stage oncology firm, has initiated a Phase 1/2 clinical trial for BBI-825, an innovative oral inhibitor of ribonucleotide reductase (RNR), as part of the STARMAP study.

In a recent Phase 1b clinical trial, MEI Pharma's drug candidate ME-344, when combined with bevacizumab, demonstrated positive results in treating patients with relapsed metastatic colorectal cancer (mCRC).

Processa Pharmaceuticals, a clinical-stage company, has introduced promising results from a Phase 1b study of its Next Generation Capecitabine (NGC-Cap) at the AACR Annual Meeting.

Enliven Therapeutics has reported encouraging early results from a Phase 1 clinical trial of ELVN-001, a novel small molecule kinase inhibitor targeting chronic myeloid leukemia (CML).

Lamassu Biotech has received approval from the FDA to commence Phase 1/2a clinical trials for its innovative cancer treatment, SA53-OS.

MEI Pharma's Board of Directors has made a strategic decision to focus on the clinical development of their drug candidates, voruciclib and ME-344, based on positive clinical data.

April 12, 2024 —Cbio A/S, a biopharmaceutical firm based in Copenhagen, has announced its financial results for 2023 and provided an update on the company's progress.

Agenus Inc. has reported new findings from its Phase 1 clinical study of BOT/BAL combination therapy for patients with metastatic colorectal cancer (CRC).